Evanta (Galipea longiflora), a tree traditionally used by the Tacana people of Bolivia, has long been applied for the treatment of diarrhea, parasites, ulcers, leishmaniasis, and as a fortifying remedy for individuals of all ages. Quinoline alkaloids have been identified as the plant’s active components. Clinical validation studies between 2007 and 2012 at Palos Blancos Hospital demonstrated that Evanta syrup and ointment achieved a 69% cure rate for cutaneous leishmaniasis among 35 treated patients, with no reported side effects, performing comparably to standard treatments such as Glucantime. Field studies also showed that Evanta syrup had promising antiparasitic effects against Ascaris spp., Strongyloides vermicularis, Trichuris trichiura, and Uncinaria spp., matching the performance of Mebendazole and Albendazole, although its effectiveness was limited against Hymenolepis nana and protozoa like Giardia lamblia. These findings support Evanta's potential as a safe and effective antiparasitic treatment. The research has been supported by several projects, including the “Biomolecules of Medicinal and Industrial Interest” program (UMSA-ASDI 2021–2025), “Chemical and Biological Validation of Aqueous Extracts of Galipea longiflora” (UMSA-ASDI 2010–2011), rural schoolchildren deworming initiatives (UMSA-IDH 2010–2014), and the “Infectious Diseases: New Therapeutic Strategies” project (UMSA-ASDI 2004–2012).